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Editorial
The last 10 years have seen major advances in the under-
standing of the pathobiology of systemic lupus erythema-
tosus (SLE). These improvements have led to discoveries
of new molecules that target specific points in the immu-
nological cascade that contribute to the immune hyperac-
tivity and loss of tolerance in this heterogeneous autoim-
mune disease. Despite a large number of clinical trials
assessing new molecules in patients with active SLE, beli-
mumab (Benlysta®) is the only biologic agent that has
been approved for clinical use. Whilst the track record
of these large and expensive clinical trials has been dis-
appointing, it has been very encouraging to see that in-
vestigators from industry and academia have not been
dissuaded from further investment to fill the huge unmet
need for better understanding of the immunopathology of
SLE and the search for novel and effective treatments.
This special issue of Immunologic Research brings to-
gether internationally acclaimed experts in the field of SLE
to provide cutting edge updates in this rapidly moving re-
search area We included original articles and reviews to
cover basic science and clinical aspects of SLE including
the possible role of infections and updates on the
antiphospholipid syndrome (APS).
The first original article by Schmidt et al. [1] investi-
gated regulatory T cells (Tregs) in the peripheral blood
and inflamed tissue including the skin and kidney in pa-
tients with SLE. A reasonable hypothesis is that autoim-
mune diseases are characterised by overexpression of
helper T cells and reduced numbers and/or function of
Tregs. However, the literature is very conflicting.
Schmidt et al. showed that activated effector T cell popu-
lations were increased in the peripheral blood of patients
with SLE but that total numbers of Treg cells were un-
changed. The numbers of regulatory T cells were similar
in the inflamed tissue to those from control diseases.
However, specific Treg subsets appeared misbalanced in
SLE patients: within CD4+CD25++ Tregs of patients with
active SLE, markers related to Treg function (CD27) and
homing (CCR6) were altered. This is a controversial area
with conflicting findings in the literature; therefore, this
study suggests that analysing subpopulations of Tregs
may be more fruitful in dissecting the potential role of
these T cells in the pathogenesis of SLE.
Hormones are clearly important in the pathogenesis of
SLE and, given that the disorder is 9–10 times more com-
mon in females, oestrogens must play a major role.
Another hormone that is emerging is prolactin, produced
by the anterior pituitary gland and other cells including
immune cells. Jara et al. [2] review the potential role of
prolactin in the innate and adaptive immune responses in
immune-neuroendocrine reactions. Hyperprolactinemia
has been demonstrated in association with active disease
in SLE. Bromocriptine, a dopamine analogue that sup-
presses prolactin secretion, may be able to reduce disease
activity and improve immune competency in animal
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models of lupus. However, this mode of treatment has not
been widely adopted in patients with SLE.
SLE is commonly a disorder of young women of child-
bearing age. Many large lupus centres have clinical services
designed to counsel women andmanage their pregnancies and
the perinatal period. Martinez-Sanchez et al. [3] describe a
prospective cohort study of 42 anti-Ro/SSA antibody-
positive women and report their pregnancy complications
(CHB, preeclampsia, preterm delivery), ultrasound data and
modes of delivery. These data complement the previously
published information in the literature and will be useful to
clinicians tasked with managing these women in their clinics.
Cardiovascular disease is over-represented in women
with SLE and whilst the risks are considerably increased,
the event rate of cardiovascular disease in SLE is relative-
ly low, making this a difficult area to study when it comes
to prevention trials. Szabo et al. [4] summarise the epide-
miology of dyslipidemia in SLE patients and review the
latest results in the pathogenesis of lipid abnormalities
and the assessment and management of dyslipidemia in
SLE. For example, patients with lupus nephritis are often
characterised by dyslipidemia and it is well recognised
that even low-grade proteinuria and renal impairment sig-
nificantly increase cardiovascular risks.
Watad el al [5] follow this article with analysis of a
large health service database in Israel which included over
5000 patients. They demonstrated in a multivariate anal-
ysis that SLE was associated with ischemic heart disease
with an odds ratio of 3.77.
Vitamin D levels are low in most, if not all, patients with
SLE for a variety of reasons. Many patients are photosensitive
and therefore have rigorous photoprotection strategies.
Marinho et al. [6] argue persuasively that vitamin D not only
has a role in the pathobiology of SLE but also that vitamin D
treatment is safe and may be effective in modulation of the
immune response in active disease. Vitamin D may also influ-
ence cardiovascular risk in SLE.
The central role of the microbiome in the maintenance
of health and its potential role in a variety of human
diseases including autoimmune rheumatic diseases is just
beginning to be explored. Katz-Agranov and Zandman-
Goddard [7] provide an excellent review of recent stud-
ies describing how alterations of the gut microbial com-
position may be correlated with SLE disease manifesta-
tions. These are early days in this exciting field and
understanding the gut microbiota may potentially lead
to exciting new therapies, perhaps using dietary manip-
ulations to treat lupus.
The possible role of viral infections in the pathogenesis
of SLE has long fascinated researchers especially given
the central importance of the interferon signature in this
disease. However, conclusive evidence has still not been
demonstrated in the literature. Hod et al. [8] review the
evidence for parvovirus infection in SLE and found that
this was very uncommon in their patients (only 3.9% of
patients). However, there appeared to be an association
between parvovirus infection and antiphospholipid anti-
bodies and these tantalising data will hopefully lead to
confirmatory studies.
Further insights into infections are described by
Mahroum et al. [9] who describe an increased prevalence
of hepatitis C virus in SLE patients. Segal et al. [10]
provide evidence for a possible role of human papilloma
virus in SLE and support Shoenfeld’s concept of SLE as
an autoimmune mosaic disease.
It is well recognised that B cell malignancies are over-
represented in patients with SLE. In a large study from
Israel, Azrielant et al. [11] utilised data from a health
service database and confirmed the increased risk of
non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, multi-
ple myeloma and other malignancies. This data empha-
sises the importance of screening patients with SLE for
haematological malignancies in this patient group.
Antiphospholipid syndrome increases the risk of pre-
mature mortality and contributes significantly to morbid-
ity in patients with SLE; therefore, the final section of this
issue is devoted to this autoimmune thrombotic disorder.
The classical autoantibodies associated with this syn-
drome are the lupus anticoagulant, anticardiolipin and
anti-β2 glycoprotein 1 antibodies. Alessandri et al. [12]
describe exciting data on the potential use of antibodies to
mutated citrullinated vimentin (MCV) as a marker for the
antiphospholipid syndrome. They found a significant cor-
relation between anti-MCV and anti-vimentin/cardiolipin
antibodies serum levels, and this data offer useful insights
into alternative tests for the diagnosis of APS.
Stroke is a feared complication of APS, and Carmel-
Neiderman et al. [13] assessed the value of classical and
alternative autoantibody profiles in patients with strokes
and carotid disease. They suggest that lower cut-off
values of these autoantibodies than those used for APS
diagnosis could be useful for risk stratification of CVA
among healthy individuals, but this clearly needs further
validation in what is a very controversial area.
Finally, the early detection of subclinical vascular dis-
ease may be a powerful tool to predict future cardiovas-
cular events. Saponjski et al. [14] used 64-multi-sliced
computed tomography to analyse lower limb vascular le-
sions and found a high prevalence of vascular lesions in
patients with APS. They argue that this technique may be
more accurate than ultrasound, but the downside is the use
of radiation.
This issue offers a compelling collection of incisive articles
for the reader to get up to date with advances in the fields of
SLE and APS, and we congratulate the many authors on their
timely contributions.
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